132 related articles for article (PubMed ID: 37506986)
21. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
[TBL] [Abstract][Full Text] [Related]
22. Interferon regulatory factor transcript levels correlate with clinical outcomes in human glioma.
Lei J; Zhou MH; Zhang FC; Wu K; Liu SW; Niu HQ
Aging (Albany NY); 2021 Apr; 13(8):12086-12098. PubMed ID: 33902005
[TBL] [Abstract][Full Text] [Related]
23. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.
Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W
Front Immunol; 2021; 12():557994. PubMed ID: 34220791
[TBL] [Abstract][Full Text] [Related]
24. Grade scoring system reveals distinct molecular subtypes and identifies KIF20A as a novel biomarker for predicting temozolomide treatment efficiency in gliomas.
Ye L; Tong S; Wang Y; Wang Y; Ma W
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9857-9876. PubMed ID: 37248320
[TBL] [Abstract][Full Text] [Related]
25. MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma.
Sun JZ; Zhang JH; Li JB; Yuan F; Tong LQ; Wang XY; Chen LL; Fan XG; Zhang YM; Ren X; Zhang C; Yu SP; Yang XJ
Dis Markers; 2021; 2021():6680883. PubMed ID: 34211612
[TBL] [Abstract][Full Text] [Related]
26. CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma.
Jiang Y; Ji Q; Long X; Wang P; Tu Z; Zhang X; Zhu X; Huang K; Li J
Front Immunol; 2022; 13():810832. PubMed ID: 35265072
[TBL] [Abstract][Full Text] [Related]
27. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
Hao YP; Wang WY; Qiao Q; Li G
Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
[TBL] [Abstract][Full Text] [Related]
28. Coiled-coil domain containing 109B is a HIF1α-regulated gene critical for progression of human gliomas.
Xu R; Han M; Xu Y; Zhang X; Zhang C; Zhang D; Ji J; Wei Y; Wang S; Huang B; Chen A; Zhang Q; Li W; Sun T; Wang F; Li X; Wang J
J Transl Med; 2017 Jul; 15(1):165. PubMed ID: 28754121
[TBL] [Abstract][Full Text] [Related]
29. Regulation of prognosis-related Siglecs in the glioma microenvironment.
Mao R; Zhou L; Yang Y; Wang P; Lin H; Zheng J; Lv G; Zhou D
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3343-3357. PubMed ID: 34472004
[TBL] [Abstract][Full Text] [Related]
30. Integrated bioinformatics analysis and experimental validation reveal ISG20 as a novel prognostic indicator expressed on M2 macrophage in glioma.
Peng Y; Liu H; Wu Q; Wang L; Yu Y; Yin F; Feng C; Ren X; Liu T; Chen L; Zhu H
BMC Cancer; 2023 Jun; 23(1):596. PubMed ID: 37380984
[TBL] [Abstract][Full Text] [Related]
31. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
32. Pan-Cancer Analysis Identifies CHD5 as a Potential Biomarker for Glioma.
Xu L; Shao F; Luo T; Li Q; Tan D; Tan Y
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955624
[TBL] [Abstract][Full Text] [Related]
33. MAPK4 predicts poor prognosis and facilitates the proliferation and migration of glioma through the AKT/mTOR pathway.
Ren J; Zheng S; Zhang L; Liu J; Cao H; Wu S; Xu Y; Sun J
Cancer Med; 2023 May; 12(10):11624-11640. PubMed ID: 36999945
[TBL] [Abstract][Full Text] [Related]
34. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.
Hu Y; Tu Z; Lei K; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive analyses indicated the association between m6A related long non-coding RNAs and various pathways in glioma.
Chen Z; Zhang W; Yan Z; Zhang M
Cancer Med; 2023 Jan; 12(1):760-788. PubMed ID: 35668574
[TBL] [Abstract][Full Text] [Related]
36. The Prognostic Value of EMT in Glioma and its Role in the Glioma Immune Microenvironment.
Ning W; Qiu Z; Ji X; Wang X; An Y; Wang S; Zhang H
J Mol Neurosci; 2020 Oct; 70(10):1501-1511. PubMed ID: 32495005
[TBL] [Abstract][Full Text] [Related]
37. Deciphering the role of QPCTL in glioma progression and cancer immunotherapy.
Liu Y; Lu S; Sun Y; Wang F; Yu S; Chen X; Wu LL; Yang H; Shi Y; Zhao K
Front Immunol; 2023; 14():1166377. PubMed ID: 37063864
[TBL] [Abstract][Full Text] [Related]
38.
Xu L; Liu Z; Wang H; Lu J; Xu J; Meng Y; Huang K; Liu B
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980973
[TBL] [Abstract][Full Text] [Related]
39. DLL3 expression and methylation are associated with lower-grade glioma immune microenvironment and prognosis.
Noor H; Whittaker S; McDonald KL
Genomics; 2022 Mar; 114(2):110289. PubMed ID: 35124175
[TBL] [Abstract][Full Text] [Related]
40. Procollagen C-protease enhancer protein is a prognostic factor for glioma and promotes glioma development by regulating multiple tumor-related pathways and immune microenvironment.
Zhao Z; Zhao J; Wang Z; Wu Y; Zhang Z; Song Z; Miao J; Liu B; Zhang S; Sun B; Zhao Z
Int J Immunopathol Pharmacol; 2022; 36():3946320221104548. PubMed ID: 35609253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
